Literature DB >> 25158939

Effect of lens status in the surgical success of 23-gauge primary vitrectomy for the management of rhegmatogenous retinal detachment: the Pan American Collaborative Retina Study (PACORES) group results.

Rafael R Caiado1, Octaviano Magalhães, Emmerson Badaró, Andre Maia, Eduardo A Novais, Francisco Rosa Stefanini, Rodrigo Milan Navarro, J Fernando Arevalo, Lihteh Wu, Nilva Moraes, Michel Eid Farah, Maurício Maia.   

Abstract

PURPOSE: To determine the effects of lens status on the success rate of primary pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment using either perfluoropropane gas (C3F8) or silicone oil (SO) tamponade.
METHODS: A retrospective chart analysis was made of 97 eyes from 92 patients with rhegmatogenous retinal detachment with no proliferative vitreoretinopathy that were treated with primary 23-gauge PPV. Eyes included in this were phakic (n = 28), pseudophakic (n = 41), or phakic eyes subject to simultaneous phacoemulsification, intraocular lens implantation, and PPV during primary rhegmatogenous retinal detachment repair (n = 28). Tamponade at the end of PPV was with either C3F8 (n = 65) or SO (n = 32). Success was defined as retinal reattachment at 1 year follow-up after a single procedure in eyes submitted to C3F8 injection; in eyes treated with SO injection, the success rate was defined as retina reattached 1 year after oil removal. Statistical comparisons were made between groups using chi-square, Fisher's exact test, Kruskal-Wallis, Mann-Whitney, and multivariate analysis. All eyes were operated by 2 experienced retina surgeons and had a minimum follow-up of 12 months.
RESULTS: The vitreoretinal redetachment rate in eyes subjected to C3F8 tamponade was significantly higher (28.6%) for phakic eyes (P = 0.011) compared with pseudophakic or phakic eyes that underwent to phacoemulsification and intraocular lens implantation (4.5%). Eyes in which SO was used at the end of the surgical procedure demonstrated a similar trend of higher reoperation rates in phakic eyes (28.6%) compared with pseudophakic or phakic eyes (8%) subjected to phacoemulsification and intraocular lens implantation; however, no statistically significant difference was observed (P = 0.201). No statistically significant differences were found between groups in relation to the number of tears (P = 0.863) and their location (inferior: P = 0.189, superior: P = 0.708, nasal: P = 0.756, and temporal: P = 0.08).
CONCLUSION: The success rates of primary 23-gauge PPV with either C3F8 or SO tamponade in pseudophakic eyes with rhegmatogenous retinal detachment was higher than the same procedure performed in phakic eyes. Still, the retrospective and limited data presented is too preliminary to suggest or recommend that practitioners perform simultaneous combined cataract surgery with retinal detachment and requires further studies in a larger and prospective design to confirm these present findings.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25158939     DOI: 10.1097/IAE.0000000000000307

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  14 in total

1.  Primary vitrectomy with short-term silicone oil tamponade for uncomplicated rhegmatogenous retinal detachment.

Authors:  Murat Karacorlu; Mumin Hocaoglu; Isil Sayman Muslubas; M Giray Ersoz; Serra Arf; Omer Uysal
Journal:  Int Ophthalmol       Date:  2017-12-18       Impact factor: 2.031

2.  Intraocular pressure outcomes after 23-G vitreoretinal surgery with two different transconjunctival sutureless sclerotomy techniques: vertical versus tunnel entry.

Authors:  Sevim Ayca Seyyar; Oguzhan Saygılı; Nesime Setge Tıskaoğlu
Journal:  Int Ophthalmol       Date:  2022-01-26       Impact factor: 2.031

Review 3.  Pars plana vitrectomy combined with phacoemulsification versus pars plana vitrectomy only for treatment of phakic rhegmatogenous retinal detachment: a systematic review and meta-analysis.

Authors:  Ahmad Mirshahi; Elias Khalilipour; Hooshang Faghihi; Hamid Riazi-Esfahani; Romina Mirshahi; Hadi Z Mehrjardi; Ehsan Najibzadeh; Abdulrahim Amini; Amin Nabavi
Journal:  Int Ophthalmol       Date:  2022-08-19       Impact factor: 2.029

4.  Changes in axial length after vitrectomy for rhegmatogenous retinal detachment combined with choroidal detachment.

Authors:  Ji-Peng Li; Jun Xu; Meng Zhao
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

5.  Outcome of primary vitrectomy in phakic patients aged younger than 50 years with rhegmatogenous retinal detachments.

Authors:  Yoshikatsu Hosoda; Shoji Kuriyama; Hidetsugu Hattori; Hisako Hayashi; Miho Matsumoto
Journal:  Jpn J Ophthalmol       Date:  2016-07-01       Impact factor: 2.447

6.  Success Rates of Vitrectomy in Treatment of Rhegmatogenous Retinal Detachment.

Authors:  Yasser Helmy Mohamed; Kozue Ono; Hirofumi Kinoshita; Masafumi Uematsu; Eiko Tsuiki; Azusa Fujikawa; Takashi Kitaoka
Journal:  J Ophthalmol       Date:  2016-07-13       Impact factor: 1.909

Review 7.  Tamponade in the surgical management of retinal detachment.

Authors:  Kamyar Vaziri; Stephen G Schwartz; Krishna S Kishor; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2016-03-16

8.  Anatomical success rate of pars plana vitrectomy for treatment of complex rhegmatogenous retinal detachment.

Authors:  Xhevat Lumi; Zala Lužnik; Goran Petrovski; Beáta Éva Petrovski; Marko Hawlina
Journal:  BMC Ophthalmol       Date:  2016-12-09       Impact factor: 2.209

9.  COMPLEX RETINAL DETACHMENT IN PHAKIC PATIENTS: Previtrectomy Phacoemulsification Versus Combined Phacovitrectomy.

Authors:  Gian Marco Tosi; Angelo Balestrazzi; Stefano Baiocchi; Antonio Tarantello; Gabriele Cevenini; Davide Marigliani; Francesco Simi
Journal:  Retina       Date:  2017-04       Impact factor: 4.256

10.  Accuracy of axial length measurements obtained by optical biometry and acoustic biometry in rhegmatogenous retinal detachment: a prospective study.

Authors:  Pear Pongsachareonnont; Sagol Tangjanyatam
Journal:  Clin Ophthalmol       Date:  2018-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.